Here,we describe a combination strategy of black phosphorus(BP)-based photothermal therapy together with anti-CD47 antibody(aCD47)-based immunotherapy to synergistically enhance cancer treatment.Tumour resistance to i...Here,we describe a combination strategy of black phosphorus(BP)-based photothermal therapy together with anti-CD47 antibody(aCD47)-based immunotherapy to synergistically enhance cancer treatment.Tumour resistance to immune checkpoint blockades in most cancers due to immune escape from host surveillance,along with the initiation of metastasis through immunosuppressive cells in the tumour microenvironment,remains a significant challenge for cancer immunotherapy.aCD47,an agent for CD47/SIRPαaxis blockade,induces modest phagocytic activity and a low response rate for monotherapy,resulting in failures in clinical trials.We showed that BP-mediated ablation of tumours through photothermal effects could serve as an effective strategy for specific immunological stimulation,improving the inherently poor immunogenicity of tumours,which is particularly useful for enhancing cancer immunotherapy.BP in combination with aCD47 blockade activates both innate and adaptive immunities and promotes local and systemic anticancer immune responses,thus offering a synergistically enhanced effect in suppression of tumour progression and in inducing abscopal effects for inhibition of metastatic cancers.Our combination strategy provides a promising platform in which photothermal agents could help to enhance the therapeutic efficacy of immunotherapy.展开更多
基金The State Key Research Development Program of China(Grant No.2019YFB2203503)the National Natural Science Fund(Grant Nos.61875138,61435010,81871358,U1801254 and 61961136001)+7 种基金the Science and Technology Innovation Commission of Shenzhen(KQTD2015032416270385,JCYJ20180307164612205 and GJHZ20180928160209731)the Natural Science Foundation of Guangdong Province(Grant No.2020A151501612)are gratefully acknowledgedsupported by Grants from the Shenzhen Overseas High-Caliber Peacock Foundation(KQTD2015071414385495)to the Shenzhen International Institute for Biomedical Research and Shenzhen ScienceInnovation Commission Project Grants(JCYJ20170411094933148 and JCYJ20170815113109175)to the Shenzhen International Institute for Biomedical ResearchThe Guangdong Basic and Applied Basic Research Foundation(2019B1515120043)the Natural Science Foundation of Guangdong Province(Grant No.2020A151501612)the Longhua District Science and Innovation Commission Project Grants(JCYJ201904)are gratefully acknowledgedthe support from the Instrumental Analysis Center of Shenzhen University(Xili Campus).
文摘Here,we describe a combination strategy of black phosphorus(BP)-based photothermal therapy together with anti-CD47 antibody(aCD47)-based immunotherapy to synergistically enhance cancer treatment.Tumour resistance to immune checkpoint blockades in most cancers due to immune escape from host surveillance,along with the initiation of metastasis through immunosuppressive cells in the tumour microenvironment,remains a significant challenge for cancer immunotherapy.aCD47,an agent for CD47/SIRPαaxis blockade,induces modest phagocytic activity and a low response rate for monotherapy,resulting in failures in clinical trials.We showed that BP-mediated ablation of tumours through photothermal effects could serve as an effective strategy for specific immunological stimulation,improving the inherently poor immunogenicity of tumours,which is particularly useful for enhancing cancer immunotherapy.BP in combination with aCD47 blockade activates both innate and adaptive immunities and promotes local and systemic anticancer immune responses,thus offering a synergistically enhanced effect in suppression of tumour progression and in inducing abscopal effects for inhibition of metastatic cancers.Our combination strategy provides a promising platform in which photothermal agents could help to enhance the therapeutic efficacy of immunotherapy.
